| 摘要 |
Disclosed is the use of a soluble fibroblast growth factor receptor 1 (FGFR1) fusion protein for the manufacture of a medicament for treating a human having a cancer, wherein the medicament is formulated for administration to the human at a dose of at least about 2 mg/kg body weight, wherein fibroblast growth factor-2 (FGF-2) plasma concentration of the human is reduced below 4 pg/ml for at least one week, wherein the human has an FGF-2 plasma concentration of at least 6 pg/ml prior to administration of the medicament, and wherein the soluble FGFR1 fusion protein comprises an FGFR1 extracellular domain linked to albumin or polyethylene glycol (PEG). |
